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Abstract Matrix metalloproteinase-9 (MMP-9) is a collageno-
lytic enzyme secreted by cancer cells and involved in invasive-
ness and metastasis. Its secretion from human ¢brosarcoma HT
1080 cells is markedly enhanced by phorbol 12-myristate 13-
acetate (PMA) and abolished by brefeldin A, an inhibitor of
ADP-ribosylation factor (ARF) activation. These results sup-
port a role for ARF in PMA-stimulated MMP-9 secretion.
Overexpression of arfaptin 1, a 39 kDa ARF-binding protein
that inhibits in vitro activation of cholera toxin ADP-ribosyl-
transferase and phospholipase D (PLD) by ARF, inhibited
PMA-stimulated MMP-9 and PLD activation. These data are
in agreement with previous results demonstrating a signi¢cant
role for PLD in regulating MMP-9 secretion.
0 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Class I ADP-ribosylation factors (ARFs) are 20 kDa small
G proteins that are important regulators of COPI (coatomer)
and clathrin coat assembly on the Golgi apparatus [1^5]. In
order to exert their e¡ects, ARFs need to be in their GTP-
bound active form, and to be N-terminally myristoylated to
enable their interaction with membranes [5]. The fungal me-
tabolite brefeldin A (BFA) inhibits large, but not small [6^8],
guanine exchange factors (GEFs) for ARF and leads to inhi-
bition of bud formation on the Golgi and consequently im-
paired secretion [4,9]. Thus, ARFs are essential for maintain-
ing regular Golgi functions. ARFs are also regulators of
phospholipase D (PLD) [10,11], suggesting that PLD might
mediate some of the e¡ects of ARFs. Indeed, several studies
implicate PLD and phosphatidic acid (PA), the product of
phosphatidylcholine hydrolysis by PLD, in Golgi functions
[12^15]. Arfaptin 1 is a 39 kDa ARF-binding protein [16]
that attenuates the e¡ects of ARF on cholera toxin ADP-
ribosyltransferase and PLD [17^19] and on the tra⁄cking of
vesicular stomatitis virus glycoprotein (VSV-G) from the en-
doplasmic reticulum (ER) and through the Golgi [18]. Arfap-
tin 1 exhibits no GEF activity or GTPase activating protein
activity towards ARF [17] and its mode of action is unclear.
In this study, we investigated the role of ARF in the secre-
tion of matrix metalloproteinase-9 (MMP-9) (also known as
gelatinase B and 92 kDa type IV collagenase) from the human
¢brosarcoma HT 1080 cell line. MMP-9 is a collagenolytic
enzyme which plays a major role in hydrolysis of the extra-
cellular matrix and the invasion of cancer cells into the circu-
lation and to secondary sites [20,21]. First we established that
MMP-9 secretion requires active ARF and could be used for
studies of ARF in the cellular level. It was shown that BFA
dose-dependently inhibited secretion of MMP-9. Further-
more, increased MMP-9 secretion was found in cells overex-
pressing ARF3 and decreased secretion in those overexpress-
ing an inactive ARF3 mutant. Taken together these ¢ndings
provide strong support for a role of ARF in phorbol 12-myr-
istate 13-acetate (PMA)-induced MMP-9 secretion. Finally,
we studied the role of arfaptin 1 in regulating MMP-9 secre-
tion. Overexpression of arfaptin 1 signi¢cantly reduced PLD
activity and MMP-9 secretion. These changes agree with pre-
vious data implicating PLD activity and PA production in the
induction of MMP-9 secretion [22]. These results suggest that
arfaptin 1 may be a regulator of some in vivo e¡ects of ARF
and may therefore a¡ect regulated secretory pathways.
2. Materials and methods
2.1. Materials
Essentially fatty acid-free bovine serum albumin (BSA), Tween 20,
PMA, sodium dodecylsulfate (SDS) and rabbit anti-actin antibody
were products of Sigma. All organic solvents were of ¢ne grade and
obtained from Fisher. FuGENE6 was a product of Roche. Horse-
radish peroxidase-labeled goat anti-rabbit antiserum was purchased
from Vector. Enhanced chemiluminescence (ECL) kit was purchased
from Amersham. Non-fat dry milk was obtained from Bio-Rad. Dul-
becco’s modi¢ed Eagle’s medium (DMEM), fetal calf serum (FCS)
and all other supplements for growth media were purchased from
Invitrogen. [9,10-3H]Myristic acid was a product of Perkin Elmer
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Life Science. Polyacrylamide 10% gels, zymogram gels, zymography
renaturing bu¡er and developing bu¡er were products of Novex.
2.2. Plasmids and vectors
pcDNA3-ARF3 and pcDNA3-G2A/Q71L-ARF3 were prepared as
described before [16].
2.3. Cell culture and transfection
Cells were maintained in DMEM, 10% FCS, 10 U/ml penicillin and
10 mg/ml streptomycin (growth medium) at 37‡C and in 10% CO2
atmosphere. For experiments, 6U105 cells were seeded in 60 mm
plates and then allowed to grow for 24 h. Prior to experiments, cells
were serum-deprived for 18 h in DMEM, 0.1% BSA. For transfection,
cells were seeded at density of 4.5U105 in 60 mm plates for 24 h.
Transfections were carried out in growth medium using FuGENE6
according to the manufacturer’s instructions. After 18 h, the medium
was replaced with fresh growth medium and 10 h later cells were
serum-deprived as detailed above.
2.4. MMP-9 secretion and activity assay
Before assay, the cell medium was replaced with fresh DMEM,
0.1% BSA containing 100 nM PMA. In experiments involving inhibi-
tion with BFA, it was added 30 min before induction with PMA.
Medium samples were collected after 7.5 h and loaded with non-re-
ducing sample bu¡er (2% SDS, 10% glycerol in 62.5 mM Tris pH 6.8)
on zymogram gels. Before developing, gels were rinsed for 30 min in
renaturing bu¡er and then 30 min in developing bu¡er at room tem-
perature. Gels were incubated in fresh developing bu¡er for 18 h at
37‡C. MMP-9 activity was indicated by the clear 92 kDa band that
appeared after staining with Coomassie brilliant blue and removing
excess dye by an 18 h rinse in water. Gels were dried and scanned and
then the image was inverted (clear to black and black to clear).
2.5. In vivo PLD assay
Serum-deprived cells were labeled for 18 h with 1 WCi/ml
[3H]myristic acid and were washed with DMEM, 0.1% BSA. Follow-
ing 20 min preincubation in DMEM, 0.1% BSA, 0.3% 1-butanol, the
cells were stimulated with, unless otherwise described, 100 nM PMA
for 20 min. Cells were washed with phosphate-bu¡ered saline (PBS)
(2.68 mM KC1, 1.47 mM KH2PO4, 8.05 mM Na2PO4, 137 mM
NaC1), 0.1% BSA, scraped with 1 ml ice-cold CH3OH and transferred
into glass tubes. CHC13 and 0.1 N HC1 were added to a ¢nal ratio of
1:1:1. The lipid-containing lower phase was collected, dried and dis-
solved in 30 Wl CH3OH, CHC13 (1:1). The samples were loaded on a
thin-layer chromatography plate which was developed in the upper
phase of H2O, ethylacetate, acetic acid and iso-octane (100:110:20:50
respectively). Tritiated phosphatidylbutanol (PtdBut) was measured
after scraping the band corresponding to the PtdBut standard (Avanti
Polar Lipids).
2.6. Cell lysis and immunoblotting
Overnight serum-deprived cells in 60 mm plates were washed with
PBS and then lysed with 200 Wl lysis bu¡er (1% NP-40, 0.5% Na-
deoxycholate, 0.1% SDS, 100 mM NaF, 10 mM Na-pyrophosphate,
2.5 mM Na3VO4 in PBS). The soluble fraction was separated by 30
min centrifugation in a bench top microcentrifuge at 14 000 rpm at
4‡C. Protein samples (15 Wg) were analyzed after SDS^polyacrylamide
gel electrophoresis (SDS^PAGE) by immunoblotting with rabbit anti-
arfaptin 1 [16] diluted 1:7500 in PBS, 0.5% Tween 20 and 5% dry milk
powder and with horseradish peroxidase-labeled secondary antibody.
Immunoblots with rabbit anti-actin antibody were carried out accord-
ing to the manufacturer’s instructions. Immunoreactive bands were
visualized by the ECL reaction.
3. Results
3.1. BFA inhibits MMP-9 secretion induced by PMA
BFA inhibits large ARF-GEFs and causes disruption of the
Golgi [4,6^9,23]. Upon treatment with BFA Golgi-dependent
tra⁄cking and secretion are abolished. Therefore, BFA inhi-
bition may be used as a marker of Golgi-dependent tra⁄ck-
ing. PMA-induced MMP-9 secretion from HT 1080 cells was
dose-dependently inhibited by BFA. Inhibition was detectable
with 10 ng/ml and 100 ng/ml produced total inhibition (Fig.
1). Since no MMP-9 secretion was detected in the absence of
PMA [19] BFA alone was not tested.
3.2. MMP-9 secretion is enhanced by overexpression of ARF3
and inhibited by overexpression of inactive ARF3
ARF3 is a member of the class 1 family of ARFs that have
been shown to regulate Golgi function [5,23]. Evidence sug-
gesting a possible involvement of the ARF pathway in secre-
tion of MMP-9 came from a previous study illustrating a
major role for PLD, a downstream e¡ector of ARF, in
MMP-9 secretion [22]. In the present study we investigated
the e¡ect of ARF itself on MMP-9 secretion. Overexpression
of wild-type ARF3 in HT 1080 cells increased PMA-induced
MMP-9 secretion by 46R 4.7% (Fig. 2, mean value from scans
of three independent experiments). We also overexpressed
G2A/Q71L-ARF3 in the cells. This mutant form of ARF3
is inactive because it cannot be myristoylated and does not
associate with Golgi [3,24]. It inhibited PMA-induced MMP-9
secretion by 22R1.9% (Fig. 2, mean value from scans of three
independent experiments), presumably by competing with en-
dogenous ARF. The e¡ect of constitutively active ARF3 mu-
tant Q71L-ARF3 [16] on MMP-9 secretion was not tested
since overexpression of this protein was associated with a
marked decline in cell viability. This was not observed with
wild-type or inactive ARF3.
3.3. Examination of PLD activity in cells overexpressing
arfaptin 1
As was demonstrated before, arfaptin 1 inhibits PLD acti-
vation by ARF in vitro [18]. However, there is no previous
report of the intracellular role of arfaptin 1 or of its e¡ect on
PLD activity in stimulated cells. In view of the evidence that
ARF activates the PLD1 isozyme [25] that is present in Golgi
[26] and that PLD or its product PA can regulate Golgi func-
tions [12^15], we tested for changes in PLD activity in cells
overexpressing arfaptin 1. As shown in Fig. 3, in cells over-
expressing arfaptin 1, the e¡ect of PMA on PLD was inhib-
ited by approximately 30%, a similar inhibition to that ob-
served on MMP-9 secretion shown later in this report.
3.4. Arfaptin 1 downregulated MMP-9 secretion induced by
PMA
Previously, it was shown that PLD regulates MMP-9 secre-
tion and PA induces it in HT 1080 cells [22]. In light of these
results and those shown herein regarding the e¡ect of ARF3
Fig. 1. BFA inhibits MMP-9 secretion in a dose-dependent manner.
Overnight serum-deprived cells were incubated with fresh DMEM,
0.1% BSA containing the indicated BFA concentrations and, after
30 min, PMA was added to 100 nM. After 7.5 h, medium samples
(5 Wl) were assayed for MMP-9 activity. The data shown are repre-
sentative of three independent experiments.
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overexpression on MMP-9 secretion, and the in vivo (Fig. 2)
and in vitro [18] inhibition of PLD activity by arfaptin 1, we
investigated the e¡ect of arfaptin 1 on MMP-9 secretion from
HT 1080 cells. As shown in Fig. 4A, transient transfection of
HT 1080 cells with increasing amounts of plasmid encoding
arfaptin 1 caused a large expression of the protein. This in-
hibited the e¡ect of PMA on MMP-9 secretion when exam-
ined in terms of amount of plasmid transfected (Fig. 4B) or of
time of MMP-9 sampling (Fig. 4C). Maximal inhibition
(33R 3.8%, mean value from three independent experiments)
was observed in cells transfected with 800 ng/60 mm plate.
Finally, the e¡ect of arfaptin 1 on MMP-9 secretion is specif-
ic. This was concluded since overexpression of arfaptin 1 did
not reduce the level of other proteins in the cells (Fig. 4D).
4. Discussion
The present report provides for the ¢rst time evidence that
ARF is required for the stimulatory e¡ect of PMA on MMP-9
secretion in HT 1080 cells. Overexpression of inactive ARF3
inhibited MMP-9 secretion from PMA-induced HT 1080 cells
whereas wild-type ARF3 markedly increased it. BFA also had
a strong inhibitory e¡ect on MMP-9 secretion at compara-
tively low concentrations. These data illustrate the require-
ment of active ARF in order to achieve MMP-9 secretion.
BFA inhibits large ARF-GEF activity [6^8,23] and thus
blocks the activation of ARF in the Golgi and causes com-
plete dissolution of this organelle [4,9,27]. Inactive G2A/
Q71L-ARF3 also inhibited MMP-9 secretion, presumably by
competing with the endogenous ARF3. Interestingly, since the
association of the G2A/Q71L-ARF3 mutant with the mem-
brane is greatly impaired, this result suggests that the compe-
tition takes place in the cytosol and not at the membrane. The
di¡erence between the partial inhibition of MMP-9 secretion
caused by overexpressing G2A/Q71L-ARF3 and the full inhi-
bition observed with BFA is presumably due their di¡erent
mechanisms of inhibiting ARF action.
Establishing MMP-9 secretion as a cellular model system
for the activity of ARF allowed us to approach an important
question, namely, the intracellular role of arfaptin 1. In vitro,
arfaptin 1 inhibits the activation of PLD1 by ARFs [17].
However, in vitro systems do not always re£ect cellular
events. To explore an in vivo role for arfaptin 1, we overex-
pressed it in HT 1080 cells. This resulted in inhibition of
PMA-stimulated PLD activity (30%) and MMP-9 secretion
(33%). These results suggest a possible role for arfaptin 1 in
regulation of secretory pathways.
Another interesting question is the involvement of PLD in
regulation of Golgi functions. In a previous study reported
elsewhere [22], the e¡ect of PMA on MMP-9 secretion was
observed to be inhibited by 1-propanol to a much greater
extent than 2-propanol, implying the involvement of PLD.
This was further supported by the stimulatory e¡ect of di-
octanoyl PA [22]. In the present study, arfaptin 1 was shown
to inhibit PMA-dependent PLD stimulation (Fig. 3) and
MMP-9 secretion (Fig. 4). Moreover, arfaptin 1 was previ-
ously implicated in inhibition of VSV-G secretion [19].
Thus, we suggest that arfaptin 1, ARF and PLD operate in
concert in regulation of Golgi functions and regulated secre-
tion. It appears that the role of arfaptin 1 is to regulate and
¢ne-tune the e¡ects of ARF on the Golgi including those that
are mediated by PLD.
An issue of interest is the mechanism(s) by which PMA
stimulates MMP-9 secretion. Previous evidence [22] has
shown that the e¡ect of PMA is mediated by protein kinase
C (PKC), but the target(s) of this kinase is unknown. Because
Fig. 3. Arfaptin 1 overexpression inhibits PLD stimulation in PMA-
treated HT 1080 cells. Cells were transfected with 800 ng/60 ml
plate of either pcDNA3 (open squares) or pcDNA3-arfaptin 1 (solid
squares) and then labeled with 1 WCi/ml [3H]myristic acid in
DMEM, 0.1% BSA. After 18 h, the cells were washed and preincu-
bated with DMEM, 0.1% BSA, 0.3% 1-butanol. Following 20 min
incubation, the cells were stimulated with the indicated concentra-
tions of PMA for 20 min. The lipids were then fractionated and
[3H]PtdBut formation was measured as described in Section 2.
[3H]PtdBut values were normalized by dividing measured cpm by
total cpm in the lipid fraction, and plotted as fold increases over
control (without PMA). Data are expressed as the meansRS.E. of
three independent experiments performed in duplicate. P6 0.05 with
respect to cells transfected with pcDNA3.
Fig. 2. E¡ects of wild-type and inactive mutant ARF3 on MMP-9
secretion in PMA-induced cells. HT 1080 cells transiently trans-
fected with either pcDNA3, pcDNA3-ARF3 or pcDNA3-G2A/
Q71L-ARF3 were serum-deprived for 18 h in DMEM, 0.1% BSA.
The medium was replaced with fresh DMEM, 0.1% BSA containing
100 nM PMA. Following 7.5 h incubation, 5 Wl medium samples
were assayed for MMP-9 activity. The data shown are representa-
tive of three independent experiments.
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the steps involved in the processing and translocation of
MMP-9 are complex and involve many proteins, it will take
more work to de¢ne the site of action of PKC.
In summary, in this study, we further characterized MMP-9
release from HT 1080 cells and its regulation by PLD, ARF
and arfaptin 1. The cellular system used herein could also be
used as a model to explore the regulation of secretion. With
this system we utilized several approaches to demonstrate the
involvement of ARF and PLD in this mechanism and, in
addition, we obtained evidence for the role of arfaptin 1.
Fig. 4. Arfaptin 1 overexpression inhibits MMP-9 secretion. HT 1080 cells were transfected with either pcDNA3 or pcDNA3-arfaptin 1 using
FuGENE6 as described in Section 2. After 24 h, cells were serum-deprived in DMEM, 0.1% BSA for 18 h. A: Cells transfected with the indi-
cated amounts of plasmid were lysed as described in Section 2 and whole cell lysates were subjected to SDS^PAGE and immunoblotting with
rabbit anti-arfaptin 1. Immunoreactive bands were visualized using the ECL reaction. B: Cells transfected with the indicated amounts of DNA
were incubated with fresh DMEM, 0.1% BSA and 100 nM PMA. After 7.5 h, 5 Wl medium samples were assayed for MMP-9 activity as de-
scribed in Section 2. C: Cells transfected with either pcDNA3 or pcDNA3-arfaptin 1 (800 ng/60 ml plate) were incubated with fresh DMEM,
0.1% BSA containing 100 nM PMA. Medium samples collected at the indicated time points were analyzed for MMP-9 secretion. D: Cells
transfected with either pcDNA3 or pcDNA3-arfaptin 1 (800 ng/60 ml plate) were lysed as described in Section 2 and whole cell lysates were
subjected to SDS^PAGE and immunoblotting with rabbit anti-actin or rabbit anti-arfaptin 1. Immunoreactive bands were visualized using the
ECL reaction. The data shown are representative of three independent experiments.
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